阿帕替尼与依托泊苷治疗复发难治小细胞肺癌的效果比较

摘要
图/表
参考文献(19)
相关文章 (15)

全文: PDF (0 KB) HTML (42 KB)
输出: BibTeX | EndNote (RIS)

摘要目的比较阿帕替尼与依托泊苷治疗复发难治小细胞肺癌（SCLC）的临床效果。方法选取2016年1月～2018年1月九江市第一人民医院收治肿瘤科的98 例复发难治SCLC 患者作为研究对象，采用计算机将其随机分为阿帕替尼组（52 例）与依托泊苷组（46 例）。阿帕替尼组患者口服阿帕替尼500 mg/d，依托泊苷组患者口服依托泊苷胶囊175 mg/d，共10 d，每21 天为1 个疗程。按照RECISIT 1.1 标准评价疗效，包括客观缓解率（ORR）及疾病控制率（DCR）；检测血清神经元特异性烯醇化酶（NSE）、胃泌素释放肽前体（ProGRP）水平变化；对患者进行随访，计算中位无进展生存期及中位总生存期；对治疗期间的不良反应发生情况进行评价。结果阿帕替尼组患者的ORR、DCR 均高于依托泊苷组，差异有统计学意义（P＜0.05）。治疗前，两组患者的NSE、ProGRP 水平比较，差异无统计学意义（P＞0.05）；两组患者治疗后的NSE、ProGRP 水平均低于治疗前，且阿帕替尼组低于依托泊苷组，差异有统计学意义（P＜0.05）。阿帕替尼组患者的中位总生存期、中位无进展生存期（5.2、4.2 个月）长于依托泊苷组（3.9、3.0个月），差异有统计学意义（P＜0.05）。阿帕替尼组患者的乏力、骨髓抑制、胃肠道反应、肝肾功能损害及心脏毒性发生率均低于依托泊苷组，高血压、蛋白尿发生率均高于依托泊苷组，差异有统计学意义（P＜0.05）；两组患者的手足综合征发生率比较，差异无统计学意义（P＞0.05）。结论阿帕替尼治疗复发难治SCLC 的效果优于依托泊苷，可作为复发难治SCLC 靶向治疗的新选择。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	石玲
	王志
	左宏波

关键词 ：小细胞肺癌, 阿帕替尼, 依托泊苷

Abstract：Objective To compare the clinical effect of Apatinib and Etoposide in the treatment of relapsed and refractory small cell lung cancer (SCLC). Methods Ninety-eight patients with relapsed and refractory SCLC addmited to the Department of Oncology in Jiujiang No.1 People′s Hospital from January 2016 to January 2018 were selected as research objects and randomly divided into Apatinib group (52 cases) and Etoposide group (46 cases) by computer. Patients in the Apatinib group received Apatinib 500 mg/d orally, and patients in the Etoposide group received Etoposide Capsules 175 mg/d orally for 10 days, with a course of treatment every 21 days. According to RECISIT 1.1 standard,the efficacy was evaluated, including objective response rate (ORR) and disease control rate (DCR). Serum levels of neuron-specific enolase (NSE) and gastrin-releasing peptide precursor (ProGRP) were detected. The patients were followed up to calculate median progression-free survival and median overall survival. The occurrence of adverse reactions during treatment was assessed. Results The ORR and DCR of the Apatinib group were higher than those of the Etoposide group, and the differences were statistically significant (P＜0.05). Before treatment, there were no statistically significant differences in the levels of NSE and ProGRP between the two groups (P＞0.05). The NSE and ProGRP levels of the two groups after treatment were lower than those before treatment, and those in the Apatinib group were lower than those in the Etoposide group, the differences were statistically significant (P＜0.05). The median overall survival and median progression-free survival (5.2, 4.2 months) of patients in the Apatinib group were longer than those in the Etoposide group (3.9, 3.0 months), and the differences were statistically significant (P＜0.05). The incidences rates of fatigue, bone marrow suppression, gastrointestinal reactions, liver and kidney damage, and cardiotoxicity in the Apatinib group were lower than those in the Etoposide group, and the incidence rates of hypertension and proteinuria were higher than those in the Etoposide group, with statistical significances (P＜0.05). There was no statistically significant difference in the incidence of hand-foot syndrome between the two groups (P＞0.05). Conclusion Apatinib is more effective in the treatment of relapsed and refractory SCLC, and can be used as a new choice for targeted therapy for relapsed and refractory SCLC.

Key words： Small cell lung cancer Apatinib Etoposide

基金资助:江西省卫生计生委科技计划项目（20197128）

引用本文:

石玲;王志;左宏波. 阿帕替尼与依托泊苷治疗复发难治小细胞肺癌的效果比较[J]. 中国当代医药, 2020, 27(25): 9-13.
SHI Ling ;WANG Zhi ;ZUO Hong-bo. Effect comparison of Apatinib and Etoposide in the treatment of relapsed and refractory small cell lung cancer. 中国当代医药, 2020, 27(25): 9-13.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2020/V27/I25/9

[1]	Liu B，Qin JW，Zhou JM.Advances in the treatment of relapsed small cell lung cancer[J].Zhongguo Fei Ai Za Zhi，2017，20（3）：192-198.
[2]	Horn L，Dahlberg SE，Sandler AB，et al.Phase Ⅱstudy of cisplatin plusetoposide and bevacizumab for previously untreated，extensive-stage small-cell lung cancer：Eastern Cooperative Oncology Group Study E3501[J].J Clin Oncol，2009，27（35）：6006-6011.
[3]	Ready NE，Dudek AZ，Pang HH，et al.Cisplatin，irinotecan，and bevacizumab for untreated extensive-stage small-cell lung cancer：CALGB 30306，a phase Ⅱstudy[J].J Clin Oncol，2011，29（33）：4436-4441.
[4]	Tiseo M，Boni L，Ambrosio F，et al.Italian，Multicenter，Phase III，Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer：The GOIRCAIFA FARM6PMFJM Trial[J].J Clin Oncol，2017，35（12）：1281-1287.
[5]	Spigel DR，Townley PM，Waterhouse DM，et al.Randomized phase Ⅱstudy of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer：Results from the SALUTE Trial[J].J Clin Oncol，2011，29（16）：2215-2222.
[6]	Noda K，Nishiwaki Y，Kawahara M，et al.Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J].N Engl J Med，2002，346（2）：85-91.
[7]	Hom L，Dahlberg SE，Sandler AB，et al.Phase Ⅱstudy of cisplatin plus etoposide and bevacizumab for prevjously untreafed，extensive-stage small-cell lung cancer：Eastem Coopemtive Oncology Gmup Study E3501[J].J Clin Oncol，2009，27（35）：6006-6011.
[8]	Spigel DR，Greco FA，Zubkus JD，et al.Phase II trial of irinotecan，carboplatin，and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer[J].J Thorac Oncol，2009，4（12）：1555-1560.
[9]	吕立丽.血管内皮生长因子在小细胞肺癌血清中的表达及意义[J].研究与临床，2013，25（1）：51-52.
[10]	Peifer M，Fernandez-Cuesta L，Sos ML，et al.Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer[J].Nat Gene，2012，44（10）：1104-1110.
[11]	Lucchi M，Mussi A，Fontanini G，et al.Small cell lung carcinoma（SCLC）：the angiogenic phenomenon[J].Eur J Cardiothorac Surg，2002，21（6）：1105-1110.
[13]	曲范杰，于韦韦，张捷.阿帕替尼联合化疗治疗晚期小细胞肺癌1 例报告及文献复习[J].中国肿瘤生物治疗杂志，2017，24（8）：923-925.
[14]	李芳芳，陶海涛.阿帕替尼用于小细胞肺癌多线治疗后的挽救治疗[J].中国肺癌杂志，2018，21（7）：565-570.
[12]	Hong W，Li H，Jin X，et al.P1.07-053 Apatinib for Chemotherapy-Refractory Extensive Stage SCLC: Results from a Single-Center Retrospective Study[J].J Torac Oncol，2017，12（1）：S729.
[15]	Yan X，Wang Q，Wang H，et al.Apatinib as maintenance therapy in extensive-stage small-cell lung cancer：results from a single-center retrospective study[J].J Cancer Res Clin Oncol，2019，145（1）：235-240.
[16]	Molina R，Augé JM，Bosch X，et al.Usefulness of serum tumor markers，including progastrin-releasing peptide，in patients with lung cancer：correlation with histology[J].Tumour Biol，2009，30（3）：121-129.
[17]	Huang Z，Xu D，Zhang F，et al.Pro-gastrin-releasing peptide and neuron-specific enolase：useful predictors of response to chemotherapy and survival in patients with small cell lung cancer[J].Clin Transl Oncol，2016，18（10）：1019-1025.
[18]	Wojcik E，Kulpa JK.Pro-gastrin-releasing peptide（Pro-GRP）as a biomarker in small-cell lung cancer diagnosis monitoring and evaluation of treatment response[J].Lung Cancer（Auckl），2017，8：231-240.
[19]	Petrovic M，Bukumiric Z，Zdravkovic V，et al.The prognostic significance of the circulating neuroendocrine markers chromogranin A，progastrin-releasing peptide and neuronspecific enolase in patients with small-cell lung cancer[J].J Med Oncol，2014，31（2）：823.